Structure-based design, synthesis, and molecular modeling studies of 1-(benzo[d]thiazol-2-yl)-3-(substituted aryl)urea derivatives as novel anti-Parkinsonian agents

Medicinal Chemistry Research

Volumn 21, Issue 9, 2012, Pages 2630-2643

  Azam, Faizul ^a,b   Prasad, Medapati Vijaya Vara ^a   Thangavel, Neelaveni ^a  

^a CMR college of Pharmacy   (India)

^b NIMS UNIVERSITY   (India)

Author keywords

Benzothiazole; Docking; Neuroprotection; Parkinson's disease; Urea derivatives

Indexed keywords

1 (BENZO[D]THIAZOL 2 YL) 3 (2 BROMOPHENYL)UREA; 1 (BENZO[D]THIAZOL 2 YL) 3 (2 CHLORO 5 (TRIFLUOROMETHYL)PHENYL)UREA; 1 (BENZO[D]THIAZOL 2 YL) 3 (2 CHLOROPHENYL)UREA; 1 (BENZO[D]THIAZOL 2 YL) 3 (2 FLUOROPHENYL)UREA; 1 (BENZO[D]THIAZOL 2 YL) 3 (2 METHOXYPHENYL)UREA; 1 (BENZO[D]THIAZOL 2 YL) 3 (2 NITROPHENYL)UREA; 1 (BENZO[D]THIAZOL 2 YL) 3 (2 TOLYL)UREA; 1 (BENZO[D]THIAZOL 2 YL) 3 (2,4 DIMETHOXYPHENYL)UREA; 1 (BENZO[D]THIAZOL 2 YL) 3 (3 CHLOROPHENYL)UREA; 1 (BENZO[D]THIAZOL 2 YL) 3 (3,4,5 TRIMETHOXYPHENYL)UREA; 1 (BENZO[D]THIAZOL 2 YL) 3 (4 BROMOPHENYL)UREA; 1 (BENZO[D]THIAZOL 2 YL) 3 (4 CHLOROPHENYL)UREA; 1 (BENZO[D]THIAZOL 2 YL) 3 (4 FLUOROPHENYL)UREA; 1 (BENZO[D]THIAZOL 2 YL) 3 (4 METHOXYPHENYL)UREA; 1 (BENZO[D]THIAZOL 2 YL) 3 (4 NITROPHENYL)UREA; 1 (BENZO[D]THIAZOL 2 YL) 3 (4 PHENOXYPHENYL)UREA; 1 (BENZO[D]THIAZOL 2 YL) 3 (4 TOLYL)UREA; 1 (BENZO[D]THIAZOL 2 YL) 3 (FURAN 2 YLMETHYL)UREA; 1 (BENZO[D]THIAZOL 2 YL) 3 (NAPHTHALEN 1 YL)UREA; ADENOSINE A2A RECEPTOR; ANTIPARKINSON AGENT; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HALOPERIDOL; LEVODOPA; MALONALDEHYDE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CATALEPSY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME ANALYSIS; LIPID PEROXIDATION; MALE; MOLECULAR DOCKING; MOLECULAR MODEL; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 84866348367     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9786-y     Document Type: Article

References (49)

1. Alanine A, Flohr A, Miller AK, Norcross RD, Riemer K (2006) Benzothiazole derivatives with activity as adenosine receptor ligands. US20060003986A1
2. Araki T, Muramatsu Y, Tanaka K, Matsubara M, Imai Y (2001) Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine) neurotoxicity in mice. Neurosci Lett 312(1):50-54 (Pubitemid 32907550)
3. Azam F (2009) Synthesis of some urea and thiourea derivatives of naphtha[1,2-d]thiazol-2-amine as anti-Parkinsonian agents that cause neuroprotection against haloperidol-induced oxidative stress in mice. Med Chem Res 18:287-308
4. Azam F (2010) Therapeutic potential of free radical scavengers in neurological disorders. In: Kozyrev D, Slutsky V (eds) Handbook of free radicals: formation, types and effects. Nova Publishers, New York, pp 57-97
5. Azam F, Alkskas IA, Ahmed MA (2009a) Synthesis of some urea and thiourea derivatives of 3-phenyl/ethyl-2-thioxo-2,3-dihydrothiazolo[ 4,5-d]pyrimidine and their antagonistic effects on haloperidol-induced catalepsy and oxidative stress in mice. Eur J Med Chem 44:3889-3897
6. Azam F, Alkskas IA, Khokra SL, Prakash O (2009b) Synthesis of some novel N4-(naphtha[1,2-d]thiazol-2-yl)semicarbazides as potential anticonvulsants. Eur J Med Chem 44:203-211
7. Azam F, Barodia SK, Anwer T, Alam MM (2009c) Neuroprotective effect of naphtha[1,2-d]thiazol-2-amine in an animal model of Parkinson's disease. J Enzyme Inhib Med Chem 24(3):808-817
8. Azam F, Ibn-Rajab IA, Alruiad AA (2009d) Adenosine A2A receptor antagonists as novel anti-Parkinsonian agents: a review of structure-activity relationships. Pharmazie 64(12):771-795
9. Azam F, El-gnidi BA, Alkskas IA (2010a) Combating oxidative stress in epilepsy: design, synthesis, quantum chemical studies and anticonvulsant evaluation of 1-(substituted benzylidene/ethylidene)-4-(naphthalen-1-yl) semicarbazides. Eur J Med Chem 45:2817-2826
10. Azam F, El-gnidi BA, Alkskas IA, Ahmad MA (2010b) Design, synthesis and anti-Parkinsonian evaluation of 3-alkyl/aryl-8-(furan-2-yl)thiazolo[5,4-e][1,2, 4]triazolo[1,5-c]pyrimidine-2(3H)-thiones against neuroleptic-induced catalepsy and oxidative stress in mice. J Enzyme Inhib Med Chem 25(6):818-826
11. Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M, Morris MJ, Mouradian MM, Chase TN (2003) Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 61:293-296 (Pubitemid 36975954)
12. Chen JF, Moratalla R, Impagnatiello F, Grandy DK, Cuellar B, Rubinstein M, Beilstein MA, Hackett E, Fink JS, Low MJ, Ongini E, Schwarzschild MA (2001) The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci USA 98(4):1970-1975 (Pubitemid 32165607)
13. Choi MM, Kim EA, Hahn HG, Nam KD, Yang SJ, Choi SY, Kim TU, Cho SW, Huh JW (2007) Protective effect of benzothiazole derivative KHG21834 on amyloid beta-induced neurotoxicity in PC12 cells and cortical and mesencephalic neurons. Toxicology 239(3):156-166 (Pubitemid 47347964)
14. Cole AG, Stauffer TM, Rokosz LL, Metzger A, Dillard LW, Zeng W, Henderson I (2009) Synthesis of 2-amino-5-benzoyl-4-(2-furyl)thiazoles as adenosine A(2A) receptor antagonists. Bioorg Med Chem Lett 19:378-381
15. Correa M, Wisniecki A, Betz A, Dobson DR, O'Neill MF, O'Neill MJ, Salamone JD (2004) The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav Brain Res 148(1-2):47-54 (Pubitemid 37543655)
16. Crocker AD, Hemsley KM (2001) An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2 dopamine receptor occupancy. Prog Neuropsychopharmacol Biol Psychiatry 25:573-590 (Pubitemid 32391539)
17. Di Fabio R, Conti N, De Magistris E, Feriani A, Provera S, Sabbatini FM, Reggiani A, Rovatti L, Barnaby RJ (1999) Substituted analogues of GV150526 as potent glycine binding site antagonists in animal models of cerebral ischemia. J Med Chem 42(18):3486-3493 (Pubitemid 29445083)
18. Discovery Studio Visualizer v2.5.1.9167, Accelrys Software Inc. Ertl P, Rohde B, Selzer P (2000) Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 43(20):3714-3717
19. Escames G, Lo'pez A, García JA, García L, Acuña-Castroviejo D, García JJ, Lo'pez LC (2010) The role of mitochondria in brain aging and the effects of melatonin. Curr Neuropharmacol 8(3):182-193
20. Flohr A, Jakob-Roetne R, Norcross RD, Riemer C (2006) Substituted benzothiazole amide derivatives. US Patent 7,019,001 B2
21. Flohr A, Jakob-Roetne R, Norcross RD, Riemer C (2007) Urea substituted benzothiazoles. US Patent 7,285,548 B2
22. Hauser RA, Hubble JP, Truong DD (2003) Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD. Neurology 61:297-303 (Pubitemid 36975955)
23. Huang SY, Zou X (2010) Advances and challenges in protein-ligand docking. Int J Mol Sci 11(8):3016-3034
24. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, Ijzerman AP, Stevens RC (2008) The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322(5905):1211-1217
25. Jana S, Sinha M, Chanda D, Roy T, Banerjee K, Munshi S, Patro BS, Chakrabarti S (2011) Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: Implications in dopamine cytotoxicity and pathogenesis of Parkinson's disease. Biochim Biophys Acta 1812(6):663-673
26. Jenner P, Olanow CW (1998) Understanding cell death in Parkinson's disease. Ann Neurol 44(3 Suppl 1):S72-S84 (Pubitemid 28423832)
27. Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF (2009) Adenosine, adenosine A2A antagonists, and Parkinson's disease. Parkinsonism Relat Disord 15(6):406-413
28. Jimonet P, Audiau F, Barreau M, Blanchard JC, Boireau A, Bour Y, Cole'no MA, Doble A, Doerflinger G, Huu CD, Donat MH, Duchesne JM, Ganil P, Gue're'my C, Honor E, Just B, Kerphirique R, Gontier S, Hubert P, Laduron PM, Le Blevec J, Meunier M, Miquet JM, Nemek C, Pasquet M, Piot O, Pratt J, Rataud J, Reibaud M, Stutzmann JM, Mignani S (1999) Riluzole series. Synthesis and in vivo "antiglutamate" activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-iminobenzothiazolines. J Med Chem 42:2828-2843 (Pubitemid 29370427)
29. Lang AE (2011) A critical appraisal of the premotor symptoms of Parkinson's disease: potential usefulness in early diagnosis and design of neuroprotective trials. Mov Disord. doi: 10.1002/mds.23609
30. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46(1-3):3-26 (Pubitemid 33653411)
31. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193(1):265-275
32. Malefyt TR, Pickford L (2010) Benzothiazole derivatives. US Patent 2010/0324286 A1
33. Molinspiration Cheminformatics, Bratislava, Slovak Republic. http://www.molinspiration.com/services/properties.html. Accessed 27 Dec 2010
34. MOPAC2009, Stewart JJP, Stewart Computational Chemistry, Version 9.03CS web: http://OpenMOPAC.net
35. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comp Chem 19:1639-1662 (Pubitemid 128590223)
36. Nakajima T, Sugawara M, Uchida S, Ohno T, Nomoto Y, Uesaka N, Nakasato Y (2010) US Patent 7718808
37. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95(2):351-358 (Pubitemid 9194347)
38. Paglia DE, Valentine WN (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70(1):158-169
39. Sams AG, Mikkelsen GK, Larsen M, Torup L, Brennum LT, Schrøder TJ, Bang-Andersen B (2010) Hit-to-lead optimization of a series of carboxamides of ethyl 2-amino-4-phenylthiazole-5-carboxylates as novel adenosine A2A receptor antagonists. Bioorg Med Chem Lett 20(17):5241-5244
40. Sanberg PR, Bunsey MD, Giordano M, Norman AB (1988) The catalepsy test: its ups and downs. Behav Neurosci 102(5):748-759
41. Schwarzschild MA, Xu K, Oztas E, Petzer JP, Castagnoli K, Castagnoli N Jr, Chen JF (2003) Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. Neurology 61(11 Suppl 6):S55-S61 (Pubitemid 37505549)
42. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M (2006) Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 29:647-654 (Pubitemid 44602262)
43. Sedlak J, Lindsay RH (1968) Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 25(1):192-205
44. Sulzer D (2007) Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 30:244-250 (Pubitemid 46667168)
45. Sun Y, Oberley LW, Li Y (1988) A simple method for clinical assay of superoxide dismutase. Clin Chem 34(3):497-500
46. The PyMOL Molecular Graphics System, Version 1.3, Schrödinger, LLC Varty GB, Hodgson RA, Pond AJ, Grzelak ME, Parker EM, Hunter JC (2008) The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates. Psychopharmacology (Berl) 200(3):393-401
47. Ye Y, Wei J, Dai X, Gao Q (2008) Computational studies of the binding modes of A2A adenosine receptor antagonists. Amino Acids 35(2):389-396
48. Young DC (2009) Computational drug design. Wiley, Hoboken, NJ
49. Zhao YH, Abraham MH, Le J, Hersey A, Luscombe CN, Beck G, Sherborne B, Cooper I (2002) Rate-limited steps of human oral absorption and QSAR studies. Pharm Res 19(10):1446-1457 (Pubitemid 35266548)